Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 14/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31759054 | 0.85 | EPHX1 (0.47) | EPHX1ACHEALDH1A1ATMHPGD | |
| SCHEMBL8800335 | 0.84 | ACHE (0.53) | EPHX1ACHEALDH1A1ATM | |
| SCHEMBL9264188 | 0.84 | EPHX1 (0.46) | EPHX1ACHEALDH1A1ATM | |
| SCHEMBL11100479 | 0.82 | EPHX1 (0.52) | EPHX1ACHEALDH1A1ATMHPGD | |
| SCHEMBL7397655 | 0.82 | ACHE (0.47) | EPHX1ACHEALDH1A1ATM | |
| Ammonia Solution, Strong SCHEMBL27626603 | 0.81 | EPHX1 (0.50) | EPHX1ACHEALDH1A1ATMHPGD | |
| SCHEMBL5201837 | 0.81 | EPHX1 (0.43) | EPHX1ACHEALDH1A1ATM | |
| SCHEMBL7396836 | 0.81 | EPHX1 (0.43) | EPHX1ACHEALDH1A1ATM | |
| SCHEMBL7773645 | 0.80 | ALDH1A1 (0.48) | EPHX1ACHEALDH1A1ATMHPGD | |
| SCHEMBL30738163 | 0.80 | NPC1 (0.42) | EPHX1ACHEALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | claimed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | claimed |
| US-20250049036-A1 | SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2025-02-13 | — | — | US | disclosed |
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-6852731-B2 | Antiviral compounds | PFIZER (US) | 2005-02-08 | — | — | US | disclosed |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | PHARMACIA & UPJOHN COMPANY | 2004-12-02 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1147093-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000044728-A1 | SUBSTITUTED BICYCLIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049036-A1 | SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | CBR3, C5, CBR1 | EPHX1 2468/4885ACHE 2945/4885ALDH1A1 3438/4885 |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | EPHX1 3612/4885ACHE 4263/4885ALDH1A1 2804/4885 |
| US-20040242884-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, IRF3, IFNAR1 | EPHX1 3554/4885ACHE 3976/4885ALDH1A1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.